Diffuse Cutaneous Systemic Sclerosis Clinical Trials

7 recruiting

Diffuse Cutaneous Systemic Sclerosis Trials at a Glance

7 actively recruiting trials for diffuse cutaneous systemic sclerosis are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Clearwater, Newport Beach, and Boston. Lead sponsors running diffuse cutaneous systemic sclerosis studies include CRISPR Therapeutics, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, and Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

Browse diffuse cutaneous systemic sclerosis trials by phase

Treatments under study

About Diffuse Cutaneous Systemic Sclerosis Clinical Trials

Looking for clinical trials for Diffuse Cutaneous Systemic Sclerosis? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Diffuse Cutaneous Systemic Sclerosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Diffuse Cutaneous Systemic Sclerosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics85 enrolled5 locationsNCT07287670
Recruiting
Phase 1Phase 2

Controlling Hyperactive Immunity With Long-lived Lymphocytes

Rheumatoid Arthritis (RA)Autoimmune Rheumatologic DiseaseDiffuse Cutaneous Systemic Sclerosis+1 more
Quell Therapeutics Limited16 enrolled6 locationsNCT07473154
Recruiting
Phase 2

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals200 enrolled127 locationsNCT06470048
Recruiting
Phase 1

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

SLE (Systemic Lupus)Diffuse Cutaneous Systemic SclerosisSystemic Sclerosis+4 more
CRISPR Therapeutics80 enrolled8 locationsNCT06925542
Recruiting
Phase 3

Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

Diffuse Cutaneous Systemic Sclerosis
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh24 enrolled1 locationNCT06936215
Recruiting
Phase 2

Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis
Second Affiliated Hospital, School of Medicine, Zhejiang University38 enrolled9 locationsNCT06375005
Recruiting
Phase 2

Open Label Extension Study of Brentuximab Vedotin in Early dcSSc

Diffuse Cutaneous Systemic Sclerosis
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's11 enrolled1 locationNCT05149768